AngioDynamics, Inc. (ANGO) Shares Bought by Tributary Capital Management LLC

Acadian Asset Management LLC lifted its stake in AngioDynamics by 15.8% in the third quarter. Acadian Asset Management LLC now owns 302,068 …

AngioDynamics logoTributary Capital Management LLC boosted its stake in shares of AngioDynamics, Inc. (NASDAQ:ANGO) by 1.4% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 503,670 shares of the medical instruments supplier’s stock after purchasing an additional 6,895 shares during the period. Tributary Capital Management LLC owned about 1.36% of AngioDynamics worth $10,139,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Wells Fargo & Company MN grew its position in AngioDynamics by 2.0% during the third quarter. Wells Fargo & Company MN now owns 1,103,646 shares of the medical instruments supplier’s stock valued at $23,993,000 after purchasing an additional 21,218 shares in the last quarter. Nordea Investment Management AB lifted its stake in AngioDynamics by 27.8% in the third quarter. Nordea Investment Management AB now owns 208,523 shares of the medical instruments supplier’s stock valued at $4,533,000 after acquiring an additional 45,410 shares during the last quarter. Acadian Asset Management LLC lifted its stake in AngioDynamics by 15.8% in the third quarter. Acadian Asset Management LLC now owns 302,068 shares of the medical instruments supplier’s stock valued at $6,568,000 after acquiring an additional 41,279 shares during the last quarter. Heartland Advisors Inc. lifted its stake in AngioDynamics by 41.0% in the third quarter. Heartland Advisors Inc. now owns 503,827 shares of the medical instruments supplier’s stock valued at $10,953,000 after acquiring an additional 146,498 shares during the last quarter. Finally, WINTON GROUP Ltd acquired a new stake in AngioDynamics in the third quarter valued at approximately $1,528,000. 98.80% of the stock is currently owned by hedge funds and other institutional investors.

ANGO has been the subject of a number of analyst reports. BidaskClub upgraded shares of AngioDynamics from a “buy” rating to a “strong-buy” rating in a research note on Friday, September 28th. Canaccord Genuity lifted their target price on shares of AngioDynamics from $20.00 to $23.00 and gave the company a “hold” rating in a research note on Monday, January 7th. Finally, Zacks Investment Research upgraded shares of AngioDynamics from a “hold” rating to a “strong-buy” rating and set a $24.00 target price for the company in a research note on Wednesday. Two research analysts have rated the stock with a hold rating, two have given a buy rating and two have issued a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $21.11.

In other news, CFO Michael Greiner sold 1,939 shares of the business’s stock in a transaction on Wednesday, November 7th. The shares were sold at an average price of $21.53, for a total value of $41,746.67. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 2.80% of the stock is currently owned by insiders.

Shares of AngioDynamics stock traded down $0.13 on Wednesday, reaching $20.81. The stock had a trading volume of 1,645 shares, compared to its average volume of 199,012. The company has a current ratio of 2.88, a quick ratio of 1.86 and a debt-to-equity ratio of 0.25. AngioDynamics, Inc. has a fifty-two week low of $15.26 and a fifty-two week high of $24.49. The stock has a market capitalization of $775.42 million, a price-to-earnings ratio of 28.15 and a beta of 0.74.

AngioDynamics (NASDAQ:ANGO) last issued its quarterly earnings data on Friday, January 4th. The medical instruments supplier reported $0.22 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.21 by $0.01. AngioDynamics had a net margin of 5.10% and a return on equity of 5.85%. The business had revenue of $91.50 million during the quarter, compared to analysts’ expectations of $89.24 million. During the same period in the previous year, the company earned $0.16 earnings per share. AngioDynamics’s revenue for the quarter was up 5.5% on a year-over-year basis. As a group, research analysts predict that AngioDynamics, Inc. will post 0.86 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This story was first published by Fairfield Current and is the property of of Fairfield Current. If you are accessing this story on another website, it was copied illegally and republished in violation of US & international copyright laws. The original version of this story can be read at https://www.fairfieldcurrent.com/news/2019/01/23/angiodynamics-inc-ango-shares-bought-by-tributary-capital-management-llc.html.

AngioDynamics Profile

AngioDynamics, Inc designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company provides AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support.

See Also: What are the benefits of momentum investing?

Institutional Ownership by Quarter for AngioDynamics (NASDAQ:ANGO)

Receive News & Ratings for AngioDynamics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for AngioDynamics and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

Zacks: Brokerages Anticipate Sierra Oncology Inc (SRRA) to Post -$0.21 Earnings Per Share

Acadian Asset Management LLC boosted its stake in Sierra Oncology by 22.4% during the third quarter. Acadian Asset Management LLC now owns …

Sierra Oncology logoWall Street analysts forecast that Sierra Oncology Inc (NASDAQ:SRRA) will announce earnings of ($0.21) per share for the current quarter, according to Zacks. Zero analysts have issued estimates for Sierra Oncology’s earnings. The highest EPS estimate is ($0.17) and the lowest is ($0.23). Sierra Oncology reported earnings of ($0.20) per share during the same quarter last year, which indicates a negative year-over-year growth rate of 5%. The firm is scheduled to report its next quarterly earnings results on Tuesday, February 26th.

On average, analysts expect that Sierra Oncology will report full year earnings of ($0.77) per share for the current year, with EPS estimates ranging from ($0.80) to ($0.73). For the next financial year, analysts expect that the business will post earnings of ($0.80) per share, with EPS estimates ranging from ($0.95) to ($0.66). Zacks Investment Research’s EPS calculations are a mean average based on a survey of research firms that follow Sierra Oncology.

Sierra Oncology (NASDAQ:SRRA) last announced its quarterly earnings data on Thursday, November 8th. The biotechnology company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.03).

A number of research firms have weighed in on SRRA. ValuEngine downgraded shares of Sierra Oncology from a “buy” rating to a “hold” rating in a research note on Tuesday, October 2nd. Zacks Investment Research downgraded shares of Sierra Oncology from a “hold” rating to a “sell” rating in a research note on Thursday, October 4th.

In other Sierra Oncology news, Director Andrew R. Allen purchased 66,000 shares of the firm’s stock in a transaction on Monday, December 10th. The shares were purchased at an average price of $1.64 per share, for a total transaction of $108,240.00. Following the completion of the purchase, the director now directly owns 66,000 shares of the company’s stock, valued at $108,240. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. 5.61% of the stock is owned by insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Bridgeway Capital Management Inc. boosted its stake in Sierra Oncology by 36.9% during the third quarter. Bridgeway Capital Management Inc. now owns 225,000 shares of the biotechnology company’s stock worth $383,000 after buying an additional 60,700 shares in the last quarter. 683 Capital Management LLC boosted its stake in Sierra Oncology by 3.5% during the second quarter. 683 Capital Management LLC now owns 1,800,000 shares of the biotechnology company’s stock worth $5,328,000 after buying an additional 60,926 shares in the last quarter. Acadian Asset Management LLC boosted its stake in Sierra Oncology by 22.4% during the third quarter. Acadian Asset Management LLC now owns 386,351 shares of the biotechnology company’s stock worth $656,000 after buying an additional 70,724 shares in the last quarter. Morgan Stanley boosted its stake in Sierra Oncology by 11.3% during the third quarter. Morgan Stanley now owns 992,516 shares of the biotechnology company’s stock worth $1,687,000 after buying an additional 100,709 shares in the last quarter. Finally, Algert Global LLC boosted its stake in Sierra Oncology by 173.8% during the third quarter. Algert Global LLC now owns 394,258 shares of the biotechnology company’s stock worth $670,000 after buying an additional 250,267 shares in the last quarter. Hedge funds and other institutional investors own 60.50% of the company’s stock.

Shares of Sierra Oncology stock traded down $0.06 during midday trading on Friday, hitting $1.35. The company had a trading volume of 2,461 shares, compared to its average volume of 183,807. The company has a market cap of $107.83 million, a price-to-earnings ratio of -1.58 and a beta of 1.68. The company has a current ratio of 14.68, a quick ratio of 14.68 and a debt-to-equity ratio of 0.05. Sierra Oncology has a 1-year low of $1.05 and a 1-year high of $3.70.

Sierra Oncology Company Profile

Sierra Oncology, Inc, a clinical stage drug development company, researches, develops, and commercializes DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer in the United States and internationally. The company’s lead drug candidate is SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1, which is in Phase 1 clinical trial to treat patients with advanced cancer.

Recommended Story: Trading Strategy

Get a free copy of the Zacks research report on Sierra Oncology (SRRA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Sierra Oncology (NASDAQ:SRRA)

Receive News & Ratings for Sierra Oncology Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Sierra Oncology and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

NXT-ID, Inc. (NASDAQ: $NXTD) Equity Research Update from Maxim Group; Spin-Off of PartX …

NXTID, Inc. (NXTD – NASDAQ – $1.25). Buy. Target Price: $2.00. Spin-Off of PartX Delayed, Probably Until Late February/ Early March – Reiterate $2 …
  • On September 21, 2018, NXTD announced its intention to spin off its Fit Pay subsidiary (to be re-named PartX), and subsequently established a record date of October 17. On October 17, NXTD shares started trading without (any value for) PartX (that is, just reflecting the value of its healthcare subsidiary, LogicMark). On December 17, it was announced that the spin-off was delayed, and the October 17 record date was withdrawn, so NXTD shares now trade with the values of both LogicMark and PartX included. A new record date has not yet been announced.
  • On January 15, NXTD announced that it had signed a letter of intent for a new $16.5M

    senior secured term loan, which will be used to pay off NXTD’s existing loan facility (which contains a covenant that effectively prohibits the spin-off). The new term loan is expected to close around late February/early March, at or about which time the spin-off should also occur. Sometime between now and then, a new record date should be announced, at which time NXTD shares should again trade without any value for PartX (that is, just reflecting the value of LogicMark).

    • Notwithstanding that NXTD shares temporarily trade (until late February/early March) with the values of both LogicMark and PartX included, our price target of $2 and our 2019 estimates are for stand-alone, post-spin LogicMark/NXTD. See page 2 for our earnings model.
    • Our price target represents, relative to other small-cap healthcare/medical devices companies, a discount to multiples of 2019 enterprise value (EV)/revenue and of 2019 EV/adjusted EBITDA, reflecting NXTD’s small market cap and early stage of development.
    • We note that there have been many positive recent developments at Fit Pay/PartX (see below).

    Details:

    Fit Pay/PartX update. Many positive recent developments include: 1) Fit Pay is going to provide tokenization services to enable SwatchPAY! contactless payments with Swatch watches; 2) GarminPay (powered by Fit Pay) was added to an 11th Garmin (GRMN – NR) smartwatch, and the network of banks supporting GarminPay now numbers 260 banks in 30 countries; and 3) Fit Pay expects to start shipping Flip, its contactless payment device for Bitcoin, on February 13. The announcement from Swatch (UHR.S – NR) is especially important, in our view, in that it “represents a big step towards making contactless and wearable payments more mainstream,” in the words of the Fit Pay press release.

    Maintain $2 PT for stand-alone, post-spin LogicMark/NXTD. Relative to other healthcare/medical devices companies, our $2 price target represents a discount to multiples of EV/revenues (3.0x versus an average of 4.9x) and to multiples of EV/adjusted EBITDA (12.9x versus an average of 18.1x). The discounts reflect NXTD’s small market cap and early stage of development, in our view. NXTD shares are currently trading at a 2019 EV/revenue multiple of 2.1x and an EV/adjusted EBITDA multiple of 9.1x.

    Recent company news:

    https://finance.yahoo.com/news/nxt-id-subsidiary-fit-pay-130000314.html

    https://finance.yahoo.com/news/garmin-paytm-ecosystem-expands-launch-130000813.html

    https://finance.yahoo.com/news/nxt-id-announces-letter-intent-130000489.html

    About Investorideas.com – News that Inspires Big Investing Ideas

    Investorideas.com is a recognized news source publishing third party news and press releases plus we create original financial content. Learn about investing in stocks and sector trends from Investorideas.com with our news alerts , articles , podcasts and videos talking about cannabis, crypto, technology including AI and IoT , mining ,sports biotech, water, renewable energy and more . Investorideas.com original branded content includes the daily Crypto Corner and Podcast, Play by Play sports and stock news column, Investor Ideas #Potcasts #Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change Podcast and the AI Eye Podcast and column covering developments in AI.

    Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp. Disclosure: NXTD is a paid PR, news and social media client on Investorideas.com more details: http://www.investorideas.com/About/News/Clientspecifics.asp

    Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

    Contact Investorideas.com

    800-665-0411

    NXT-ID, Inc. (NASDAQ:NXTD)

    is a Featured tech company on Investorideas.com

    Visit Profile page: https://www.investorideas.com/CO/NXT/

    Get News Alerts on NXT-ID, Inc.

    Investorideas.com Newswire

    Disclaimer/Disclosure:

    Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp. Disclosure: Nxt-ID, Inc. (NXTD) is a long term paid news publication and PR client of Investorideas.com. details at https://www.investorideas.com/About/News/Clientspecifics.asp

    Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

Related Posts:

  • No Related Posts

Small Canadian Marijuana Stock Rallies 20.4% in a Single Day — and Could Rise Even Further

… unlike Canopy Growth and Aurora Cannabis, who already enjoyed massive investor exposure and wide international publicity while still on the TSX.

Investors in Village Farms International Inc.(TSX:VFF) saw a nice 20.39% rally in the stock price on Monday as the greenhouse operator and new cannabis grower released some welcome news of desired progress and announced new listing plans.

Why did the stock rally that much?

Village Farms updated the market that its Pure Sunfarms joint venture with Emerald Health Therapeutics has completed the conversion of a 1.1million square foot green house into cannabis production and has since made an application to Health Canada for production licensing.

The facility is already partially licensed for both production and sales and it commenced sales in September last year, just in time for recreational marijuana sales debut by October 17. At a projected capacity of 75,000 kilograms of dried cannabis per annum, the facility ranks among the largest cannabis production facilities in Canada right now.

That said, it seems that the facility expansion news wasn’t the main catalyst for the rally, as Emerald Health shares only gained just over 2% during the day’s trading. Emerald Health has a 50% interest in the joint venture.

This brings us to the next big news in the Monday press release.

The company announced its application to list its shares for trading on the NASDAQ, one of the largest global stock exchanges with high liquidity and unrivalled market depth. Dual listing on this big exchange that is located in the largest stock market in the world is expected to result in improved trading liquidity, increased investor awareness and better access to cheaper financing for the firm and these attributes may be expected to result in better price discovery ad better valuation of the company’s issued shares.

Actually, listing on the NASDAQ resulted in a strong surge in the share price for Cronos Group Inc when it dual listed earlier, and the benefits were somehow realized for other Canadian marijuana stocks like Canopy Growth.

Smaller issuers may enjoy a more magnified reaction to the share price when dual listing on a major U.S. exchange, unlike Canopy Growth and Aurora Cannabis, who already enjoyed massive investor exposure and wide international publicity while still on the TSX.

I would therefore ascribe the sharp surge in Village Farms equity valuation mainly to the NASDAQ listing news.

Is there room for further share price growth?

Village Farms is one of the largest and longest operating greenhouse operators in North America, with decades of experience in growing and supplying fresh vegetable produce to the United States and Canada.

The company has over 9,000,000 square feet of greenhouse production space that it could convert to higher margin cannabis crops that generate increased revenue of up to 10-15 times that of its Canadian vegetable production.

The option to allocate more of the existing greenhouse assets to marijuana production could result in significant margin expansion, and the company has the capacity to cheaply produce over 300,000 kilograms of cannabis annually from retrofitted facilities at under $1 cost per gram. The company could easily rank among the top four producers in Canada in no time.

However, the lack of provincial supply agreements in its marketing portfolio is currently a concern, as it may be forced to rely on low margin wholesale sales to other licensed producers, but there is some promise, as negotiations with the provinces are said to be underway while recreational sales are picking up due to current product shortages on the spot market.

Further, the company is keen on investing in the recently opened U.S. hemp market, where it already has a strong physical presence and massive agricultural productive assets. Although investors may experience some dilution as the company seeks financial capital to embark on a hemp journey, I wouldn’t mind some dilution if the new capital generates higher growth multiples.

I like the fact that the firm is a founder led company with the founder and CEO holding a near 20% stake in the firm. This attribute aligns interests between management and investors, and such firms have been known to outperform their non-founder led counterparts over the long term.

Investor takeaway

There is a significant room for growth on this vegetable grower that is rapidly transforming itself into a serious cannabis operation. That said, I would like to see more distribution arrangements and branding efforts for the company to claim a top position among today’s cannabis giants.

You might be missing out on one of the biggest opportunities in Canadian investing history…

Marijuana was legalized across Canada on October 17th, and a little-known Canadian company just unlocked what some experts think could be the key to profiting off the coming marijuana boom.

Besides making key partnerships with Facebook and Amazon, they’ve just made a game-changing deal with the Ontario government.

One grassroots Canadian company has already begun introducing this technology to the market – which is why legendary Canadian investor Iain Butler thinks they have a leg up on Amazon in this once-in-a-generation tech race.

This is the company we think you should strongly consider having in your portfolio if you want to position yourself wisely for the coming marijuana boom.

Learn More About This TSX Stock Now

Related Posts:

  • No Related Posts

Analysts Suggest to Buy Technology Stock: Broadcom Inc. (AVGO)

Analysts Suggest to Buy Technology Stock: Broadcom Inc. (AVGO) … to year to date performance) how Broadcom Inc. (AVGO) has been moved; …

On Tuesday, Jan 22, Shares of Broadcom Inc. (AVGO) were valued at $258.29 and moved -0.97% as of a recent closing trade. A total volume of 3.72 million shares were traded versus to average volume of 3.96 million shares.

Performance

Broadcom Inc. (AVGO) held 412.00 million outstanding shares currently. The company have shares float of 403.96 million. Now have a look at past performance (weekly performance to year to date performance) how Broadcom Inc. (AVGO) has been moved; whether it performed well or not. AVGO reported a change of 2.96% over the last week and performed 5.90% over the last month while its year to date (YTD) performance revealed an activity trend of 1.58%. The stock’s quarterly performance specifies a shift of 13.28%, and its last twelve month performance is stands at -3.04% while moved 22.80% for the past six months.

Twenty-day SMA is useful at identifying swing trading trends lasting twenty days. Shorter moving average timeframes are more sensitive to price fluctuations and can pick up on trend changes more quickly than longer-term moving averages. However, these more frequent signals may also result in more “whipsaws”, resulting in erroneous trade signals. AVGO recently closed with rise of 4.55% to its twenty-Day SMA. This short time frame picture represents an upward movement of current price over average price of last twenty days.

52 week High and Low

Broadcom Inc. (AVGO) shares have been seen trading -5.68% off its 52 week- peak value and changed 30.81% from its 52 week-bottom price value. The “percentage off the 52-week high or low” refers to when a stock current price is relative to where it has traded over the last 52 weeks. This gives investors an idea of how much the security has moved in the last year and whether it is trading near the top, middle or bottom of the range.

Analysts have suggested a mean rating of 2.00 on the shares. This is based on a 1-5 numeric scale where Rating Scale: 1.0 Strong Buy, 2.0 Buy, 3.0 Hold, 4.0 Sell, 5.0 Strong Sell.

Relative Strength Index (RSI)

Broadcom Inc. (AVGO)’s Relative Strength Index (RSI) is 59.50. RSI is a technical indicator of price momentum, comparing the size of recent gains to the size of recent losses and establishes oversold and overbought positions. Average True Range (14) for Broadcom Inc. (AVGO) is stands at 8.54. ATR is a volatility indicator. Volatility measures the strength of the price action, and is often overlooked for clues on market direction.

Over the past week, the company showed volatility of 2.72%. Moving out to look at the previous month volatility move, the stock is at 3.45%.

Beta measures volatility or systematic risk, of a stock or a portfolio in comparison to the market as a whole. 1 shows stock moves with market. 1 indicates more volatile than the market. The stock’s beta is 0.72.

Related Posts:

  • No Related Posts